selected scholarly activity
-
conferences
- Direct Oral Anticoagulants in the Real World: Insights into Canadian Health Care Providers’ Understanding of Medication Dosing and Use. Journal of Thrombosis and Haemostasis. 638-638. 2015
- Efficacy and safety of different bridging regimens of parenteral anticoagulation after mechanical valve replacement. European Heart Journal. 814-814. 2013
-
journal articles
- Central venous access device insertion and perioperative management of patients with severe haemophilia A. Blood Coagulation and Fibrinolysis. 27:156-159. 2016
- Diagnosis and treatment of intracranial hemorrhage in children with hemophilia. Blood Coagulation and Fibrinolysis. 24:23-27. 2013
- Diagnosis and treatment of intracranial hemorrhage in children with hemophilia. Blood Coagulation and Fibrinolysis. 24:23-27. 2013
- Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. Journal of Thrombosis and Haemostasis. 10:2494-2502. 2012
- Ifosfamide induced Fanconi syndrome. BMJ Case Reports. 2011:bcr1020114950-bcr1020114950. 2011
- Comparing bleed frequency and factor concentrate use between haemophilia A and B patients. Haemophilia. 17:872-874. 2011
- Immune tolerance induction for a patient with factor IX inhibitors - a case report. Haemophilia. 17:315-315. 2011
- Undetected factor VIII in a patient with type 3 von Willebrands disease mistaken as severe haemophilia A. Haemophilia. 15:1258-1261. 2009
- Utilization of recombinant activated factor VII in southern Ontario in 85 patients with and without haemophilia. Haemophilia. 13:518-526. 2007
- Trends in the utilization and wastage of coagulation factor concentrates: the application of a regional tracking programme. Haemophilia. 13:271-278. 2007
- Canadian multi‐institutional survey of immune tolerance therapy (ITT) – experience with the use of recombinant factor VIII for ITT. Haemophilia. 12:1-6. 2006
- Comparing hand‐held computers and paper diaries for haemophilia home therapy: a randomized trial. Haemophilia. 10:698-704. 2004
- Health status and health‐related quality of life associated with von Willebrand disease. American Journal of Hematology. 73:108-114. 2003
- Developing a tracking system for coagulation factor concentrates in southern Ontario. Transfusion. 43:556-562. 2003
- Health status and health‐related quality of life associated with hemophilia. American Journal of Hematology. 71:152-160. 2002
- Efficacy and Safety of the Factor VIII/von Willebrand Factor Concentrate, Haemate-P/Humate-P: Ristocetin Cofactor Unit Dosing in Patients with von Willebrand Disease. Thrombosis and Haemostasis. 87:224-230. 2002
- Effect of the Factor V Leiden Mutation on the Clinical Expression of Severe Hemophilia A. Thrombosis and Haemostasis. 83:387-391. 2000
- Familial Evans Syndrome. Journal of Pediatric Hematology/Oncology. 21:244-247. 1999
- Causes of death in Canadians with haemophilia 1980-1995. Association of Hemophilia Clinic Directors of Canada.. Haemophilia. 4:714-720. 1998
- A Detailed Comparison of the Performance of the Standard versus the Nijmegen Modification of the Bethesda Assay in Detecting Factor VIII:C Inhibitors in the Haemophilia A Population of Canada. Thrombosis and Haemostasis. 79:872-875. 1998
- Carrier detection strategy in haemophilia A: the benefits of combined DNA marker analysis and coagulation testing in sporadic haemophilic families. British Journal of Haematology. 70:321-326. 1988
- MASSIVE TRANSPLACENTAL HEMORRHAGE. Obstetrical and Gynecological Survey. 30:600-601. 1975
- Massive transplacental hemorrhage: clinical manifestations in the newborn.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 112:585-589. 1975
- Selective IgA Deficiency in Rh‐Negative Women. Vox Sanguinis. 27:87-91. 1974
- Antibodies to IGA in Pregnancy and in Recipient of Rho(D) Immune Globulin (Human). Transfusion. 12:394-399. 1972
- HL-A genotype of patients with acute lymphoblastic leukaemia. Humangenetik. 13:234-237. 1971